Epidemiology of cancer and diabetes

New Post Public Reply Private Reply Replies (0) Message Board
wowhappens28
115
Epidemiology of cancer and diabetes

https://www.diapedia.org/associated-disorders...ign=buffer

There is a growing body of evidence to support a relationship between diabetes and cancer. Epidemiologic studies have observed a higher incidence of various types of cancer among individuals with diabetes, particularly type 2 diabetes, as compared with people without diabetes. People with diabetes also have poorer survival than non-diabetics after a diagnosis of cancer. The relationship between diabetes and cancer incidence and/or mortality is however complex, and potential sources of bias need to be considered with care when interpreting the data. Furthermore, the association with diabetes varies in important respects between cancer types, which need to be considered on an individual basis rather than collectively when assessing the relationship between diabetes and cancer.

Introduction
Studies from the early part of the last century suggested that people with diabetes were less likely to die of cancer than non-diabetic individuals, an observation that can be explained by ‘competing risks’ (i.e., causes of death) - in this case the high mortality from accelerated arterial disease in the diabetic population. As cardiovascular risk management in diabetes becomes more effective, the morbidity and mortality associated with cancer will inevitably increase in the diabetic population.

Many recent studies have in contrast confirmed a strong positive association between diabetes and many types of tumour[1][2]. Furthermore, people with diabetes have a shorter survival after a diagnosis of cancer than non-diabetic individuals, although this might once again be due in part to competing risks (higher diabetes-associated mortality).[3]

Diabetes type and cancer
Since 90-95% of people with diabetes in the general population have type 2 diabetes[4], and belong to an age group more commonly affected by cancer, much more is known about the relationship between cancer and type 2 diabetes than about type 1. The comparison between the conditions is of particular interest in that a similar pattern of cancer risk in the type 2 and type 1 populations would support a causal role for hyperglycemia, whereas a different pattern would point to non-glycemic factors.

Risk for Individual Cancers in type 2 diabetes
Summary data from meta-analyses of cancer risks in type 2 diabetes are shown in the figure.

The strongest association between diabetes and incident cancer is for Pancreatic cancer[5] and Liver cancer and diabetes[6] ; however, ‘reverse causality’ (where the cancer itself leads to diabetes) may in part overestimate the magnitude of this relationship. The risk for Endometrial cancer is approximately twice as high in the diabetic population.[7]

Individuals with diabetes also have a moderately elevated risk (20-40%) of incident Breast Cancer, Colorectal cancer, Bladder cancer and diabetes, thyroid and kidney. There is no consistent evidence for an increased risk of lung or ovarian cancers in the diabetic population.[8]

A notable exception is Prostate cancer and diabetes, where men with diabetes have a 15% lower risk of prostate cancer than non-diabetic men, possibly due to lower endogenous testosterone levels in men with diabetes.[9][10]

Cancer Mortality and Diabetes
Individuals with diabetes also have a higher risk of dying from various cancers, including prostate cancer, compared with individuals who do not have diabetes. In general, findings for increased cancer mortality reflect cancer incidence. Among cancer patients, those with diabetes have a higher risk of mortality if they have colorectal, liver, pancreatic and bladder cancers.

There is less consistent evidence around the risk of mortality among diabetic individuals with breast and endometrial cancer.[3] Competing risks may potentially confound comparisons between survival in the diabetic and non-diabetic populations, since people with diabetes have a higher cardiovascular mortality than those without.

Biologic plausibility
Associations at the epidemiologic level correlate with results from biologic experiments. The leading hypothesis for the association between diabetes and cancer is that hyperinsulinemia (i.e., high insulin levels), a common feature of diabetes, also promotes the growth of cancer cells, which typically express the insulin receptor.[1]. See Hyperinsulinemia and cancer. Although hyperinsulinemia is the leading biologic hypothesis, hyperglycemia (see Hyperglycemia and cancer) and chronic inflammation may also play a role in promoting cancer growth.[1][2]

Shared risk factors for cancer
The relationship between diabetes and cancer is unique to each cancer site and differs by sex and the type of diabetes (i.e., type 1 vs. type 2). Both diabetes and cancer are chronic diseases associated with an aging population. Aside from age and sex, modifiable risk factors such as obesity, smoking, alcohol use, diet, physical inactivity and other lifestyle choices are factors that increase the risk for both diseases. This combination of common non-modifiable (i.e., age, sex, genetics, etc) and modifiable (i.e., smoking, diet, etc) risk factors increases the likelihood for an individual with diabetes to also develop cancer and adds to the complexity of describing excess cancer risk in the diabetic population.

Methodological considerations
Given the indolent and slowly-progressing nature of both cancer and diabetes, ascertaining cancer rates in the diabetic population is challenging. Ideally, studies should have two cancer-free cohorts of individuals: one with newly diagnosed diabetes and another without diabetes, both of which should be followed for a long enough duration for cancer to develop (i.e., several years).[2]

Some epidemiologic methods used to describe cancer rates in individuals with diabetes may be prone to ‘detection bias’ (where a visit to a doctor at the time of diabetes diagnosis makes it more likely for the doctor to find an undiagnosed cancer), which may overestimate the risk of cancer in people with newly diagnosed diabetes. [11][12] Other studies may be prone to ‘lead time bias’ (where individuals must survive a certain amount of time after a diagnosis of diabetes to be included in a study), which may underestimate the rates of cancer in the diabetes population.[13] Other methodologic considerations surrounding epidemiologic research of diabetes and cancer were highlighted in two recent consensus papers published by members of the international Diabetes and Cancer Research Consortium.[2][3]
Scroll down for more posts ▼

Top 10 Most Recent News Articles

HERVolution's HERV-K Antigens: A Cancer Breakthrough?

Updated Category News Views 120

Digging into HERVolution's Game-Changing Data Picture HERVolution in the spotlight, rolling out data that could shake up our approach to cancer immunotherapy. The big headline? HERV-K antigens might just be the whistle-blower we've been looking for to get the immune system off the bench and onto the field. How's that for a kick in the conventional wisdom of cancer...

Continue Reading
DAR Logs Massive 587,000 Service Hours Nationwide

Updated Category News Views 92

A Month of Patriotism and Service You've got to hand it to the Daughters of the American Revolution (DAR)—when they commit, they go all in. This year, they turned their usual Day of Service into a full-blown Month of Service, packing in over 587,000 hours of volunteering nationwide. From historic spots to food pantries, DAR members showed up, and honestly, it's the kind...

Continue Reading
Landis+Gyr's Q2 Gains and Future Strategies

Updated Category News Views 0

Landis+Gyr's Multi-Faceted Financial Leap In the unpredictable landscape of energy tech, Landis+Gyr has thrown down some noteworthy cards in their latest financial disclosures. We're talking a Q2 net revenue sitting pretty at $269.2 million, and it's no mistake they landed a record-smashing adjusted gross margin of 38.0%. All this while wrangling an order intake of $170.3...

Continue Reading
Casio's CMK?100: A Lightweight Marvel Blending Style and Utility

Updated Category News Views 77

A Timepiece That Redefines Everyday Elegance There's a new player in the vast realm of watches, and it's got tongues wagging: the Casio CMK?100. You don’t see that blend of style, comfort, and practicality grow on trees, my friend. Casio’s new offering, the CMK?100, wears its purpose on its titanium sleeve: lightweight and stylish, it’s a suave addition to any wrist...

Continue Reading
Yale's $10M Inflammation Initiative: Future Health Impact

Updated Category News Views 25

Yale’s Inflammation Research: Beyond the Basics Inflammation. It’s the kind of battle your own body wages from within, and Yale School of Medicine’s fresh $10 million grant from the Blavatnik Family Foundation means they’re marching deeper into the trenches. This is not another academic exercise; it’s about digging out the roots of diseases that are tough to pin...

Continue Reading
MPLX Adds Industry Veterans to Board Leadership

Updated Category News Views 38

A New Era for MPLX's Board Nothing shakes up the scene like announcing two heavyweights joining the board, and that's exactly what MPLX LP (NYSE: MPLX) just pulled off. Micheal G. Dunn and Bruce L. Niemeyer are coming onboard, effective November 1, 2026. With pedigrees that could make any industry insider nod in approval, these guys bring decades of experience to the...

Continue Reading
7-Eleven Rolls Out Korean Flavors in Bold Menu Shift

Updated Category News Views 155

7-Eleven's New Global Menu Twist October 2026 sees 7-Eleven, Inc. whip out an intriguing move, venturing east with its new Flavors of Korea menu. They're not just changing the game in convenience store aisles; they're dancing to the beat of global flavors—a shake-up fit for the world's largest convenience retailer. Think about bodega basics getting a spicy Korean...

Continue Reading
From Missouri to Market: A New Spin on Turkey Calls

Updated Category News Views 24

Innovating the Turkey Call Game You want innovation? Well, wrap your head around this: a Missouri inventor is flipping the script on turkey mouth calls. The goal? To ditch the wrinkles and make turkey hunting that much smoother. It might seem a bit niche, but when you've been around long enough, you know these 'niche' ideas can sometimes hatch golden eggs for investors....

Continue Reading
Bechtel's $1M Push for Wyoming's Skilled Trades Future

Updated Category News Views 204

Wyoming's Bid for Skilled Trades Revolution You’d think with all the talk about tech and white-collar jobs, we’ve forgotten the backbone that keeps the world ticking—skilled trades. Turns out, Bechtel hasn’t. The company just tossed a cool million at Wyoming's Laramie County Community College and Western Wyoming College. What’s that doing? It's jumpstarting...

Continue Reading
Trump Quotation Book Takes Unbiased Approach

Updated Category News Views 0

In the ever-evolving dance of political discourse, a new book strides onto the stage: Not My President, published by Palmetto Publishing. It’s a bold compilation of presidential utterances, capturing the words of Donald J. Trump in all their unvarnished glory. Stripped of analysis or comedic flair, each entry stands alone like a solitary figure at a cocktail party,...

Continue Reading

Top 5 Most Recently Viewed Articles

Empowering Tomorrow's Healers: Dr. Zarkadas' Scholarship

Updated Category News Views 116

Empowering Future Medical Leaders The Dr. Konstantinos Zarkadas Scholarship for Future Doctors is now open for applications. This scholarship invites undergraduate students committed to the field of medicine to apply for a prestigious award. The scholarship, which amounts to a one-time award of $1,000, aims to assist a deserving student who exemplifies both academic...

Continue Reading
Pharma Two B and Hepion Pharmaceuticals Merge for Growth

Updated Category News Views 47

Pharma Two B and Hepion Pharmaceuticals Announce Merger KIRYAT ONO, ISRAEL and EDISON, N.J. — Pharma Two B Ltd., a leading late-stage pharmaceutical company focused on treating Parkinson’s Disease, has officially announced its merger with Hepion Pharmaceuticals, Inc. (Nasdaq: HEPA), which specializes in addressing chronic liver diseases. They have filed a registration...

Continue Reading
Applied Graphite Technologies Grants Stock Options to Team

Updated Category News Views 186

Applied Graphite Technologies' Recent Developments Applied Graphite Technologies Corporation (AGT) has made significant strides in its operations recently by granting 2,350,000 stock options to its consultants, directors, and officers. These options are set at an exercise price of $0.07, and they come with a five-year term, expiring on August 13, 2030. This move...

Continue Reading
Jefferson Solutions Group Sets Course for Strategic Growth

Updated Category News Views 7

Jefferson's Big Move: A Strategic Overhaul The winds of change are blowing over at Jefferson Solutions Group. This May, the company announced a heavy-duty strategic reorganization to better align with its astronomical ambitions for long-term growth. If you're the type that's got a soft spot for high-impact solutions and government gigs, pay attention, because this shift...

Continue Reading
Unbeatable Security Solutions for Your Home This Summer

Updated Category News Views 191

Unbeatable Security Solutions for Your Home This Summer As summer vacation approaches, ensuring the safety of your home becomes vital. Reolink, known for its innovative solutions in visual technology, has announced early Prime Day deals that will make securing your property both convenient and affordable. With these impressive offers, you can invest in top-rated security...

Continue Reading